-
'I want to be Eala': Philippine sensation sparks tennis boom at home
-
Australia probes three near-misses at Sydney Airport
-
US says lower oil prices, not Iran's nuclear program, are now top priority in war
-
Classy Tanzid puts Bangladesh in firm charge against Australia
-
Most Asian stocks track Wall St record as US data ease rate fears
-
Schwarber smacks two homers to power Philles' MLB Field of Dreams win
-
China's viral 'spicy strips' take a bite of global snack market
-
Pakistan's date workers toil through rising heat
-
Shelton does the double in Canada
-
New trend of injecting banned peptides to 'optimise' body
-
'Shock' gloves for US immigration agents fuel potential abuse fears
-
Eddie Jones senses Japan's time has come against Australia
-
New Zealand Football withdraws support for Infantino, urges review
-
UK vote count under way in Farage, Binface showdown
-
Hopes fade in Colombia as window to find quake survivors shuts
-
US, Mexico conduct security exercises near border
-
Trump announces tariffs of up to 100% on imported drones
-
Swiatek rolls past Rybakina for WTA Toronto title
-
Spieth among five sharing Memphis lead as PGA playoffs open
-
Vance says low oil prices are top US goal in Iran conflict
-
Boats rescue tourists as forest fire flames threaten Greek beaches
-
Hunt bags Euro sprint double, Ceh keeps discus title
-
Good vibes powering Djokovic return to Cincinnati
-
'Dream come true': Owners reunite with pets in quake-hit Colombia
-
Britain's Hunt wins 200m for European sprint double
-
US stocks gain after benign inflation data, oil prices retreat
-
Draper dumped as Norrie saves face for Britain in Cincinnati
-
LeBron's Sixers in spotlight as full 2026-27 NBA schedule revealed
-
England opener Gay out for duck in Pakistan warm-up
-
Kennedy Center board votes to restore Trump name: reports
-
Europe swelters under fresh wave of extreme heat
-
Barcelona agree to sell Torres to PSG: media
-
French Olympic gold medallist Florent Manaudou announces retirement
-
Romania shuts nuclear plant as Danube drops
-
Tourists rescued by boat as forest fire threatens Greek beaches
-
Millions of Europeans struggle with another wave of extreme heat
-
Indicted Raul Castro reappears after months out of public view
-
Israel reopens once-closed West Bank settlement
-
Italian teen Curtis breaks women's 50m backstroke world record for second time
-
Taylor to captain New Zealand for first time against Bulls
-
Taulagi steps out of 'comfort zone' with code switch to French Top 14 new boys
-
Carrick urges Man Utd to push for more signings to boost title bid
-
Leicester's Thai owners put troubled club up for sale: reports
-
'This was my World Cup' says Somali ref after UEFA Super Cup
-
Stocks steady as US inflation worries ease, oil slips
-
Survivors tell of horror of Zimbabwe ferry sinking as death toll hits 46
-
Porsche to end production of flagship electric car: report
-
Juventus forward Vlahovic signs three-year Besiktas deal
-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.AbuTaha--SF-PST